Please consult Arterial Education for more information.
1.5 hours Educational Activities
Please consult Arterial Education for more information.
5.5 hours Measuring Outcomes
Please consult Arterial Education for more information.
1.0 hour Reviewing Performamnce
By the end of this audit, participants will be able to:
· Assess the impact of morbidity, mortality, and healthcare burden associated with HF, including the high rates of hospitalisation, rehospitalisation, and the significant economic costs, emphasising the need for improved management and adherence to guidelines
· Describe the key components of GDMT for HF (including ACEIs, ARNIs, BBs, MRAs, and SGLT2Is) and discuss their proven benefits in reducing mortality and hospitalisations in patients with HFrEF and HFpEF
· Identify common barriers to the effective implementation of GDMT in clinical practice, including under-prescription, patient-related factors, and systemic challenges, and explore strategies to overcome these barriers
· Interpret the role of NT-proBNP testing to aid in diagnosing HF, particularly in non-hospital settings, and outline how these tests can enhance detection, improving diagnostic efficiency and cost-effectiveness
· Apply evidence-based guidelines for the management of HF in clinical practice, including the appropriate use of pharmacological treatments based on ejection fraction to optimise patient care and outcomes.
AUS
can